GleamWall
中文EN

CRMD CorMedix Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1410098 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY96.3%
TTM net income YoY-60.7%
TTM EPS YoY-71.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin38.3%
Net margin15.4%
FCF margin74.1%
EBITDA margin46.0%

Returns

ROE15.3%
ROA7.7%
ROIC (approx.)27.3%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.90x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$54.52M$101.93M$127.43M$131.34M$101.55M$39.74M$39.08M$31.21M
Cost of revenue$14.21M$14.51M$12.01M$11.17M$7.57M$1.81M$1.54M$1.12M
Gross profit$30.00M$77.13M$105.12M$107.31M$93.08M$37.87M$37.48M$30.03M
R&D expense$7.04M$6.68M$7.21M$8.60M$5.10M$2.44M$3.19M$1.73M
SG&A expense$17.90M$15.09M$21.72M$23.57M$25.45M$9.50M$9.69M$7.11M
Operating income-$6.62M$42.91M$63.66M$59.13M$51.35M$19.54M$20.12M$12.94M
Interest expense———$1.82M$948,242$6,671$10,007$10,007
Pretax income-$16.45M$38.73M$55.65M$56.45M$52.58M$20.35M$20.64M$13.46M
Income tax-$1.73M$12.74M$17.04M$42.43M-$55.99M$522,000$0$0
Net income-$14.72M$25.99M$38.60M$14.02M$108.56M$19.83M$20.64M$13.46M
EBITDA$3.91M$53.45M$74.20M$59.42M$55.14M$19.71M$20.29M$13.02M
EPS (basic)-0.190.330.48—1.420.290.32—
EPS (diluted)-0.190.290.43—1.260.280.30—
Weighted avg. shares (diluted)78.45M92.48M92.98M—86.21M71.92M68.97M—
Balance sheet
Cash & equivalents$355.15M$256.69M$178.09M$144.84M$48.49M$159.31M$66.29M$40.76M
Short-term investments$0$0$0$3.69M$7.22M$31.40M$11.22M$11.04M
Receivables$76.71M$161.31M$154.81M$171.23M$158.57M$42.91M$54.61M$51.65M
Inventory$43.14M$38.58M$30.73M$29.72M$28.92M$9.63M$7.49M$7.60M
Current assets$502.99M$480.55M$383.11M$367.05M$259.54M$248.06M$144.86M$114.58M
PP&E, net$8.56M$7.85M$6.17M$5.96M$4.35M$1.64M$1.73M$1.83M
Goodwill$30.00M$30.00M$30.00M$30.00M$17.52M———
Intangibles$348.17M$358.47M$368.77M$379.07M$390.01M$1.74M$1.79M$1.84M
Total assets$917.75M$904.05M$815.64M$826.14M$750.86M$252.60M$149.58M$118.85M
Current liabilities$207.29M$187.40M$128.78M$174.27M$133.64M$31.71M$34.39M$33.84M
Long-term debt———$150,000$150.00M———
Total debt———$150,000$150.00M———
Total liabilities$456.04M$443.22M$378.59M$420.83M$376.73M$31.97M$34.69M$34.19M
Shareholders' equity$461.71M$460.83M$437.05M$405.31M$374.13M$220.63M$114.89M$84.66M
Net debt———-$144.69M$101.51M———
Shares outstanding79.48M77.67M78.40M79.26M78.35M74.62M67.71M64.41M
Cash flow statement
Operating cash flow$89.70M$86.24M$42.38M$94.46M$30.86M$29.99M$19.74M-$5.61M
Capital expenditure$1.91M$561,000$729,000$1.72M$506,000$24,000$10,000$9,869
Free cash flow$87.79M$85.68M$41.65M$92.74M$30.35M$29.97M$19.73M-$5.62M
Investing cash flow-$1.91M-$561,000$2.96M$3.30M-$291.32M-$20.21M-$195,000-$304,161
Financing cash flow$10.67M-$7.07M-$12.10M-$1.41M$150.53M$83.24M$6.09M$11.28M
Depreciation & amortization$10.53M$10.54M$10.54M$294,096$3.79M$163,000$162,000$81,727
Stock-based compensation$3.94M$4.08M$4.58M$3.59M$4.07M$2.68M$3.50M$1.19M
Share buybacks$0$6.39M$11.09M—$0$0$0—

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.